Close Menu

Regulus

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,133,876
Filed: Dec. 30, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Title: Method and Medicament for Inhibiting the Expression of a Given Gene
Patent Number: 8,114,851
Filed: Oct. 31, 2007
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,110,558
Filed: Dec. 31, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Regulus Therapeutics said this week that that Australian Patent Office has recently granted certain claims in a company-controlled patent family covering the use of microRNA-122 in treating hepatitis C.

The discovery triggered a milestone payment of an undisclosed amount, Regulus said.

Gregory Hannon

Mice treated with a miR-33 antagonist displayed increased HDL-C, enhanced reverse cholesterol transport to the plasma, liver, and feces, and reductions in plaque size and lipid content.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.